Promoted Content

Promoted Content

All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Dr. Reddy's Laboratories

Virtual Booth Offering a portfolio of products & services including APIs, CMO services, generics, biosimilars & differentiated formulations.

INDIA India

Contact Supplier

CPhI Japan 2021

Attending

Request a Meeting Now

Dr. Reddy’s Laboratories Presents Preclinical Data at SITC 2020 Demonstrating Significant Improvement in Tumor Growth Inhibition and Overa...

Contact the Supplier

Lead Product(s): Denileukin Diftitox,Anti-PD-1 agent

Therapeutic Area: Oncology Product Name: E7777

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Eisai

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 09, 2020

Details:

Combination of E7777 with an anti-PD-1 agent provided clear benefit both in terms of tumor growth control, and a highly significant improvement in overall survival.

Aurigene

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

CPhI India 2021

Participation Not Confirmed

Update your events

Exelixis In-Licenses Aurigene’s CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Trial in Advanced Solid Tumors

Contact the Supplier

Lead Product(s): XL102

Therapeutic Area: Oncology Product Name: XL102

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Exelixis

Deal Size: $29.5 million Upfront Cash: $10.0 million

Deal Type: Licensing Agreement December 07, 2020

Details:

Exelixis has exercised exclusive option for Aurigene’s novel CDK7 inhibitor under the companies’ July 2019 agreement. Exelixis has now assumed responsibility for the future clinical development, commercialization, and global manufacturing of the compound now known as XL102.